Interclean Shanghai

Sensyne Health COVID risk prediction algorithm achieves UK regulatory approval

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media PackNow

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI...

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

FDA Widens Early Alert Initiatives for...

The Food and Drug Administration (FDA) has gone on to...

First U.S.-Based Experience Center of Siemens...

Siemens Healthineers has gone ahead and launched its first...

Sensyne Health plc, the UK Clinical AI company, announces that its SYNE-COVTM machine learning algorithm for COVID risk prediction has achieved regulatory approval for use in the UK.

About SYNE-COV

SYNE-COV analyses over 60 variables in the patient electronic health record to generate a prediction of the likelihood of a COVID positive patient developing severe disease, requiring ventilation or admission to intensive care. It provides the risk prediction, together with an explanation of the result, to help clinicians manage patients admitted to hospital with COVID infection.

The SYNE-COV product was developed in collaboration between Sensyne and the Chelsea & Westminster Hospitals NHS Foundation Trust This is the first algorithm developed from the SENSETM clinical and operational algorithm engine to achieve UK regulatory approval. SENSE generates Clinical AI algorithms (called SYNEs) from the analysis of data in patient electronic health records to provide decision support to clinicians. The Company has several algorithms currently in development across multiple medical conditions, which subject to regulatory approval, it intends to market to healthcare providers in the UK and internationally.

Following regulatory approval, Sensyne is now able to market SYNE-COV across the UK. Sensyne will market the algorithm to NHS Trusts in order to help them with COVID preparedness and to deploy the algorithm in good time for the 2021/22 winter season

Latest stories

Related stories

FDA Approves Zenix Monitor-Defibrillator from ZOLL

ZOLL®, which happens to be an Asahi Kasei company...

MHRA in the UK Accelerates AI Rollout in the NHS

The Medicines and Healthcare Products Regulatory Agency (MHRA) from...

FDA Widens Early Alert Initiatives for All Medical Devices

The Food and Drug Administration (FDA) has gone on to...

First U.S.-Based Experience Center of Siemens Healthineers

Siemens Healthineers has gone ahead and launched its first...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »